Q1 Earnings Estimate for Harrow Issued By HC Wainwright

Key Points

• Harrow, Inc. is expected to earn $0.13 per share in Q1 2026 according to HC Wainwright, which maintains a "Buy" rating and a $64.00 target price for the stock.
• The company reported Q2 earnings with $0.24 EPS, significantly exceeding analyst estimates by $0.23, despite a slight miss in revenue expectations.
• Recent institutional investments saw notable increases, including Voya Investment Management growing its stake by 4,035.5%, highlighting strong interest in Harrow from large investors.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Harrow in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of $0.13 for the quarter. HC Wainwright has a "Buy" rating and a $64.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.24 EPS and Q4 2026 earnings at $0.34 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Several other brokerages have also recently commented on HROW. William Blair assumed coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating for the company. Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price for the company. Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, BTIG Research raised their price target on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $64.67.

Harrow Stock Down 0.6%

HROW traded down $0.2210 during trading on Thursday, reaching $38.0990. 392,036 shares of the stock traded hands, compared to its average volume of 482,171. The stock's 50-day simple moving average is $33.34 and its two-hundred day simple moving average is $28.92. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -152.46 and a beta of 0.41.

Institutional Trading of Harrow

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Harrow during the fourth quarter worth approximately $25,000. Quarry LP bought a new position in Harrow during the first quarter worth $32,000. Raymond James Financial Inc. acquired a new position in Harrow during the 2nd quarter valued at $48,000. Tower Research Capital LLC TRC grew its position in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of Harrow during the fourth quarter valued at about $78,000. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.